© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 05, 2015
Treating sensitizing EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) leads to better outcomes compared with standard chemotherapy.
February 20, 2014
Anti-angiogenic therapy aims to disrupt blood supply to tumors and has proven clinical benefit in nonsquamous non-small cell lung cancer (NSCLC).
November 11, 2013
Activating EGFR mutations are associated with response to TKIs. Afatinib (Gilotrif) is an oral, irreversible ErbB family TKI that targets EGFR, HER2, and ErbB4. Afatinib is being formally evaluated in the LUX-Lung clinical trial program for NSCLC.